Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L17 pseudogene 46 (RPL17P46) is a processed, non-functional pseudogene in the human genome. It does not encode a protein and has no known functions, biological activity, or disease relevance by itself. Pseudogenes like RPL17P46 represent genetic copies of ribosomal protein genes, such as RPL17, that have accumulated disabling mutations and are not translated into functional protein. The existence of many ribosomal protein pseudogenes, including RPL17P46, reflects the extensive retrotransposition activity observed in vertebrate evolution, but there is no evidence that RPL17P46 is involved in cellular regulation or disease[9][11][1][6][10]. Direct activities or therapeutic relevance are absent.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L17 pseudogene 46 (RPL17P46).